KR101714819B1 - 암 줄기 세포를 표적화하는 신규 화합물 및 조성물 - Google Patents

암 줄기 세포를 표적화하는 신규 화합물 및 조성물 Download PDF

Info

Publication number
KR101714819B1
KR101714819B1 KR1020127027267A KR20127027267A KR101714819B1 KR 101714819 B1 KR101714819 B1 KR 101714819B1 KR 1020127027267 A KR1020127027267 A KR 1020127027267A KR 20127027267 A KR20127027267 A KR 20127027267A KR 101714819 B1 KR101714819 B1 KR 101714819B1
Authority
KR
South Korea
Prior art keywords
cancer
compound
polymorph
pharmaceutical composition
furan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127027267A
Other languages
English (en)
Korean (ko)
Other versions
KR20130056227A (ko
Inventor
치앙 지아 리
데이비드 리겟트
유쯔이 리
웨이 리
Original Assignee
보스톤 바이오메디칼, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 보스톤 바이오메디칼, 인크. filed Critical 보스톤 바이오메디칼, 인크.
Publication of KR20130056227A publication Critical patent/KR20130056227A/ko
Application granted granted Critical
Publication of KR101714819B1 publication Critical patent/KR101714819B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
KR1020127027267A 2010-03-19 2011-03-21 암 줄기 세포를 표적화하는 신규 화합물 및 조성물 Active KR101714819B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US31589010P 2010-03-19 2010-03-19
US31588610P 2010-03-19 2010-03-19
US61/315,886 2010-03-19
US61/315,890 2010-03-19
US32581410P 2010-04-19 2010-04-19
US61/325,814 2010-04-19
PCT/US2011/029281 WO2011116398A1 (en) 2010-03-19 2011-03-21 Novel compounds and compositions for targeting cancer stem cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020167032280A Division KR101908208B1 (ko) 2010-03-19 2011-03-21 암 줄기 세포를 표적화하는 신규 화합물 및 조성물

Publications (2)

Publication Number Publication Date
KR20130056227A KR20130056227A (ko) 2013-05-29
KR101714819B1 true KR101714819B1 (ko) 2017-03-09

Family

ID=47678419

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167032280A Active KR101908208B1 (ko) 2010-03-19 2011-03-21 암 줄기 세포를 표적화하는 신규 화합물 및 조성물
KR1020127027267A Active KR101714819B1 (ko) 2010-03-19 2011-03-21 암 줄기 세포를 표적화하는 신규 화합물 및 조성물

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020167032280A Active KR101908208B1 (ko) 2010-03-19 2011-03-21 암 줄기 세포를 표적화하는 신규 화합물 및 조성물

Country Status (15)

Country Link
US (4) US9084766B2 (enExample)
EP (1) EP2547334B1 (enExample)
JP (1) JP5602935B2 (enExample)
KR (2) KR101908208B1 (enExample)
CN (3) CN103002890A (enExample)
AU (2) AU2011227022C1 (enExample)
BR (2) BR122021025776B1 (enExample)
CA (2) CA2946899C (enExample)
DK (1) DK2547334T3 (enExample)
ES (1) ES2659541T3 (enExample)
MX (2) MX370721B (enExample)
NZ (1) NZ602328A (enExample)
RU (1) RU2571661C2 (enExample)
SG (1) SG184063A1 (enExample)
WO (1) WO2011116398A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2736564A1 (en) 2007-09-10 2009-03-19 Boston Biomedical, Inc. Novel compositions and methods for cancer treatment
RU2015142279A (ru) * 2010-03-19 2018-12-28 Бостон Байомедикал, Инк. Новые соединения и композиции для нацеливания на злокачественные стволовые клетки
KR101908208B1 (ko) * 2010-03-19 2018-10-15 보스톤 바이오메디칼, 인크. 암 줄기 세포를 표적화하는 신규 화합물 및 조성물
SG11201508358RA (en) * 2013-04-09 2015-11-27 Boston Biomedical Inc 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
CN106163284A (zh) * 2014-02-07 2016-11-23 北京强新生物科技有限公司 3‑取代的羰基萘并[2,3‑b]呋喃衍生物或其药学上可接受的盐
EP3153508B1 (en) 2014-06-09 2020-03-18 Kyoto Pharmaceutical Industries, Ltd. Naphthofuran derivatives for use as anticancer agents
AU2016247319A1 (en) 2015-04-17 2017-11-02 Boston Biomedical, Inc. Methods for treating cancer
EA201792288A1 (ru) 2015-04-17 2018-02-28 Бостон Биомедикал, Инк. Способы лечения рака
US20180140572A1 (en) 2015-06-03 2018-05-24 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
US10329267B2 (en) 2015-07-17 2019-06-25 Sumitomo Dainippon Pharma Co., Ltd. Method for producing 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione
WO2017079864A1 (en) * 2015-11-12 2017-05-18 Hangzhou Yier Biotech Co., Ltd. Treatment of cancers related to chronically active ras
JP2019506392A (ja) 2016-01-20 2019-03-07 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
WO2017160978A1 (en) 2016-03-15 2017-09-21 Boston Biomedical, Inc. Cell cultures and use thereof
CA3029596A1 (en) 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP2020512377A (ja) 2017-03-30 2020-04-23 ボストン バイオメディカル， インコーポレイテッド がんを処置および／または防止するための組成物
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
JP7513286B2 (ja) 2018-10-12 2024-07-09 １グローブ バイオメディカル カンパニー， リミテッド 化学療法難治性がんの治療のための新しい併用薬方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009036099A1 (en) * 2007-09-10 2009-03-19 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1049490A1 (ru) * 1982-05-18 1983-10-23 Ордена Трудового Красного Знамени Институт Химии Ан Мсср (3 @ ,9 @ ,9 @ )-6,6,9 @ -Триметилтранспергидронафто(2,1- @ )фуран,в качестве душистого компонента парфюмерной композиции
JPH1121284A (ja) 1997-06-30 1999-01-26 Kotobuki:Kk フラノナフトキノン誘導体及びこれを含有する医薬
US20060142271A1 (en) * 2002-09-17 2006-06-29 Klaus Muller Novel lapacho compounds and methods of use thereof
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
US20100298402A1 (en) * 2007-11-06 2010-11-25 Orchid Research Laboratories Limited Stilbene derivatives as pstat3/il-6 inhibitors
KR101908208B1 (ko) * 2010-03-19 2018-10-15 보스톤 바이오메디칼, 인크. 암 줄기 세포를 표적화하는 신규 화합물 및 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009036099A1 (en) * 2007-09-10 2009-03-19 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors

Also Published As

Publication number Publication date
KR20130056227A (ko) 2013-05-29
NZ602328A (en) 2014-11-28
AU2011227022B2 (en) 2015-11-19
BR112012023661A2 (pt) 2020-11-24
AU2016200953B2 (en) 2017-07-27
CA2793526C (en) 2018-05-01
CA2946899C (en) 2018-03-06
CN103002890A (zh) 2013-03-27
CN107721958B (zh) 2024-08-23
RU2571661C2 (ru) 2015-12-20
DK2547334T3 (en) 2018-02-19
MX394137B (es) 2025-03-24
AU2011227022A1 (en) 2012-09-27
AU2011227022C1 (en) 2016-04-21
SG184063A1 (en) 2012-10-30
CN107375260A (zh) 2017-11-24
JP5602935B2 (ja) 2014-10-08
BR122021025776B1 (pt) 2022-12-27
US9084766B2 (en) 2015-07-21
AU2016200953A1 (en) 2016-03-03
US20160271099A1 (en) 2016-09-22
EP2547334A1 (en) 2013-01-23
CA2793526A1 (en) 2011-09-22
WO2011116398A1 (en) 2011-09-22
JP2013522325A (ja) 2013-06-13
US20150183756A1 (en) 2015-07-02
EP2547334A4 (en) 2013-08-14
US20130034591A1 (en) 2013-02-07
KR20160135375A (ko) 2016-11-25
MX2012010434A (es) 2013-01-29
US20180193303A1 (en) 2018-07-12
CA2946899A1 (en) 2011-09-22
KR101908208B1 (ko) 2018-10-15
US9381184B2 (en) 2016-07-05
RU2012144421A (ru) 2014-04-27
EP2547334B1 (en) 2017-11-15
MX370721B (es) 2019-12-20
CN107721958A (zh) 2018-02-23
ES2659541T3 (es) 2018-03-16
CN107375260B (zh) 2023-10-24

Similar Documents

Publication Publication Date Title
KR101714819B1 (ko) 암 줄기 세포를 표적화하는 신규 화합물 및 조성물
US9730909B2 (en) Methods for targeting cancer stem cells
CN106211758B (zh) 2-乙酰基萘并[2,3-b]呋喃-4,9-二酮用于治疗癌症的用途
JP6246169B2 (ja) がん幹細胞を標的とするための新規の方法
AU2015218436A1 (en) Novel Methods For Targeting Cancer Stem Cells
HK1239527A1 (en) Novel compounds and compositions for targeting cancer stem cells
HK1229744A1 (en) 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20121018

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150813

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20150813

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151202

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160820

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20151202

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20161118

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20160820

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20160602

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20150813

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20161222

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20161121

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20160820

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20160602

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20150813

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20170303

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20170303

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20200220

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20210222

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20220225

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20230221

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20240214

Start annual number: 8

End annual number: 8